Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
The pandemic prompts only a slight drop in medtech approvals.
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
2019 was an average year for medtech M&A. 2020, not so much.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.